Literature DB >> 19457806

Challenges in clinical prostate cancer: role of imaging.

Gary J Kelloff1, Peter Choyke, Donald S Coffey.   

Abstract

OBJECTIVE: This article reviews a recent 2-day workshop on prostate cancer and imaging technology that was conducted by the Cancer Imaging Program of the National Cancer Institute. The workshop dealt with research trends and avenues for improving imaging and applications across the clinical spectrum of the disease.
CONCLUSION: After a summary of prostate cancer incidence and mortality, four main clinical challenges in prostate cancer treatment and management-diagnostic accuracy; risk stratification, initial staging, active surveillance, and focal therapy; prostate-specific antigen relapse after radiation therapy or radical prostatectomy; and assessing response to therapy in advanced disease-were discussed by the 55-member panel. The overarching issue in prostate cancer is distinguishing lethal from nonlethal disease. New technologies and fresh uses for established procedures make imaging effective in both assessing and treating prostate cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19457806      PMCID: PMC2893141          DOI: 10.2214/AJR.09.2579

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  98 in total

1.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 2.  Imaging in oncology from the University of Texas M. D. Anderson Cancer Center: diagnosis, staging, and surveillance of prostate cancer.

Authors:  Vikas Kundra; Paul M Silverman; Surena F Matin; Haesun Choi
Journal:  AJR Am J Roentgenol       Date:  2007-10       Impact factor: 3.959

3.  Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.

Authors:  C Hofer; C Laubenbacher; T Block; J Breul; R Hartung; M Schwaiger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

4.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

Authors:  T R DeGrado; R E Coleman; S Wang; S W Baldwin; M D Orr; C N Robertson; T J Polascik; D T Price
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

5.  MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model.

Authors:  Nobuyuki Oyama; Joonyoung Kim; Lynne A Jones; Nicole M Mercer; John A Engelbach; Terry L Sharp; Michael J Welch
Journal:  Nucl Med Biol       Date:  2002-11       Impact factor: 2.408

6.  Multimodal and three-dimensional imaging of prostate cancer.

Authors:  Zhenghong Lee; D Bruce Sodee; Martin Resnick; Gregory T Maclennan
Journal:  Comput Med Imaging Graph       Date:  2005-09       Impact factor: 4.790

7.  Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy.

Authors:  Cherry T Thomas; Patrick T Bradshaw; Brad H Pollock; James E Montie; Jeremy M G Taylor; Howard D Thames; Patrick W McLaughlin; David A DeBiose; David H Hussey; Richard L Wahl
Journal:  J Clin Oncol       Date:  2003-05-01       Impact factor: 44.544

8.  Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils.

Authors:  H Hricak; S White; D Vigneron; J Kurhanewicz; A Kosco; D Levin; J Weiss; P Narayan; P R Carroll
Journal:  Radiology       Date:  1994-12       Impact factor: 11.105

Review 9.  Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.

Authors:  Robert D Loberg; Jeffery R Fielhauer; Brian A Pienta; Scott Dresden; Patty Christmas; Linda M Kalikin; Karin B Olson; Kenneth J Pienta
Journal:  Urology       Date:  2003-12-29       Impact factor: 2.649

10.  The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.

Authors:  John F Ward; Michael L Blute; Jeffrey Slezak; Erik J Bergstralh; Horst Zincke
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

View more
  51 in total

1.  Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.

Authors:  David M Schuster; Bital Savir-Baruch; Peter T Nieh; Viraj A Master; Raghuveer K Halkar; Peter J Rossi; Melinda M Lewis; Jonathon A Nye; Weiping Yu; F DuBois Bowman; Mark M Goodman
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

2.  Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma.

Authors:  Bital Savir-Baruch; David M Schuster; Nashwa Jarkas; Viraj A Master; Peter T Nieh; Raghuveer K Halkar; Jonathon A Nye; Melinda M Lewis; Ronald J Crowe; Ronald J Voll; Vernon M Camp; Leah M Bellamy; David L Roberts; Mark M Goodman
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

3.  A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer.

Authors:  Jelena Levi; Ataya Sathirachinda; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

4.  Ultrasonographic Follow-up of the Multistep Protocol for Prostate Cancer Induction in Wistar Rats.

Authors:  MÁrio Ginja; Paula A Oliveira; Ana I Faustino-Rocha; Fernanda Seixas; Rita Ferreira; Jessica Silva; Maria J Pires; Margarida Fardilha
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 5.  Focused ultrasound surgery in oncology: overview and principles.

Authors:  Clare M C Tempany; Nathan J McDannold; Kullervo Hynynen; Ferenc A Jolesz
Journal:  Radiology       Date:  2011-04       Impact factor: 11.105

6.  PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.

Authors:  Mariya Shapovalova; John K Lee; Yingming Li; Donald J Vander Griend; Ilsa M Coleman; Peter S Nelson; Scott M Dehm; Aaron M LeBeau
Journal:  Cancer Res       Date:  2019-09-17       Impact factor: 12.701

7.  System Integration and Preliminary Clinical Evaluation of a Robotic System for MRI-Guided Transperineal Prostate Biopsy.

Authors:  Niravkumar A Patel; Gang Li; Weijian Shang; Marek Wartenberg; Tamas Heffter; Everette C Burdette; Iulian Iordachita; Junichi Tokuda; Nobuhiko Hata; Clare M Tempany; Gregory S Fischer
Journal:  J Med Robot Res       Date:  2018-05-15

8.  MR Safe Robot, FDA Clearance, Safety and Feasibility Prostate Biopsy Clinical Trial.

Authors:  Dan Stoianovici; Chunwoo Kim; Doru Petrisor; Changhan Jun; Sunghwan Lim; Mark W Ball; Ashley Ross; Katarzyna J Macura; Mohamad Allaf
Journal:  IEEE ASME Trans Mechatron       Date:  2016-10-20       Impact factor: 5.303

9.  Technical Note: A deuterated 13 C-urea reference for clinical multiparametric MRI prostate cancer studies including hyperpolarized pyruvate.

Authors:  Collin J Harlan; Zhan Xu; Keith A Michel; Christopher M Walker; Sanjaya D Lokugama; Gary V Martinez; Mark D Pagel; James A Bankson
Journal:  Med Phys       Date:  2020-05-11       Impact factor: 4.071

Review 10.  New agents and techniques for imaging prostate cancer.

Authors:  Atif Zaheer; Steve Y Cho; Martin G Pomper
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.